^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:HER2 Negative Breast Cancer
    Drug:Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) +
    Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SABCS 2023
    Title:

    A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer

    Published date:
    12/02/2023
    Excerpt:
    We set out to determine the recommended phase 2 dose (RP2D) for the COP/Fulvestrant (FUL)/Abemaciclib (ABE) combination...Eligible patients (pts) included men or women with ER+, HER2- metastatic breast cancer (MBC)...There were 5 partial responses and 3 stable diseases lasting for ≥24 weeks. Clinical benefit rate was 36.4% (8/22, 95%CI: 17.19% ~59.34%).
    Secondary therapy:
    fulvestrant